Author

Menkara Henry

Moffitt Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Andriy MarusykiD· 2 shared Bina DesaiiD· 2 shared Bruna PelliniiD· 2 shared Eric B. HauraiD· 2 shared David BasantaiD· 1 shared Denise KalosiD· 1 shared Dung‐Tsa Chen· 1 shared Gina S. Nazario· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andriy MarusykORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacokinetic Acceleration via CYP3A4 Hyperactivation as a Clinically Actionable Mechanism of Targeted Therapy Resistance in NSCLC

Pragya Kumar, Menkara Henry, Julia Pelesko, Bina Desai, Malgorzata Tyczynska Weh, Ramu Kakumanu, Min Liu, Natália Souza Nunes Siqueira, Robert Vander Velde, Viktoriya Marusyk, Jyllica Aurelio, Eric B. Haura, Jhanelle Gray, Bruna Pellini, David Basanta, Andriy Marusyk

This paper identifies CYP3A4 hyperactivation as a tumor-extrinsic resistance mechanism in NSCLC, showing it reduces drug exposure and leads to resistance, and proposes dosing optimization and CYP3A4 inhibition as solutions.

bioRxiv · May 20, 2026 · PreprintCancer Biology

Trastuzumab deruxtecan combination strongly enhances responses and overcomes sotorasib resistance in KRASG12C-mutant NSCLC

Hilal Özakıncı, Bina Desai, Denise Kalos, Dung‐Tsa Chen, Menkara Henry, Hitendra Singh Solanki, Theresa A. Boyle, Humberto E. Trejo Bittar, Gina S. Nazario, Eric B. Haura, Andriy Marusyk, Bruna Pellini

This study shows that combining trastuzumab deruxtecan with sotorasib improves responses in KRASG12C-mutant NSCLC and overcomes resistance, but HER2 expression levels influence treatment effectiveness.

bioRxiv · Dec 17, 2024 · PreprintCancer Biology